Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9

Diabetes

Volumn 54, Issue 10, 2005, Pages 2988-2994

  Lankas, George R ^a   Leiting, Barbara ^a   Roy, Ranabir Sinha ^a   Eiermann, George J ^a   Beconi, Maria G ^a   Biftu, Tesfaye ^a   Chan, Chi Chung ^b   Edmondson, Scott ^a   Feeney, William P ^a   He, Huaibing ^a   Ippolito, Dawn E ^a   Kim, Dooseop ^a   Lyons, Kathryn A ^a   Ok, Hyun O ^a   Patel, Reshma A ^a   Petrov, Aleksandr N ^a   Pryor, Kelly Ann ^a   Qian, Xiaoxia ^a   Reigle, Leah ^a   Woods, Andrea ^a   Wu, Joseph K ^a   Zaller, Dennis ^a   Zhang, Xiaoping ^a   Zhu, Lan ^a   Weber, Ann E ^a   Thornberry, Nancy A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

(1 VALYLPYRROLIDIN 2 YL)BORONIC ACID; 1 [[2 AMINO 2 [1 (4 IODOPHENYL)SULFONYL]PYRROLIDIN 3 YL] 1 OXOETHYL]THIAZOLIDINE; 2 (2 AMINO 3 METHYL 1 OXOPENTAN 1 YL) 1,3 DIHYDRO 2H ISOINDOLE; 2 [4 [[[[1 [3 AMINO 4 (2,5 DIFLUOROPHENYL) 1 OXOBUTYL] 2 PYRROLIDINYL]CARBONYL]AMINO]METHYL]PHENOXY] 3 METHYLBUTANOIC ACID; 4 NITROBENZYL [5 AMINO 6 OXO 6 (1 PIPERIDINYL)HEXYL]CARBAMATE; 4 NITROBENZYL [5 AMINO 6 OXO 6 (1 PYRROLIDINYL)HEXYL]CARBAMATE; 4 NITROBENZYL [5 AMINO 6 OXO 6 (1,3 THIAZOLIDIN 3 YL)HEXYL]CARBAMATE; 4 OXO 4 [3 (TRIFLUOROMETHYL) 5,6 DIHYDRO[1,2,4]TRIAZOLO[4,3 A]PYRAZIN 7(8H) YL] 1 (2,5 DIFLUOROPHENYL)BUTAN 2 AMINE FUMARATE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPEPTIDYL PEPTIDASE IX; DIPEPTIDYL PEPTIDASE VIII; HORMONE; INCRETIN; ISOLEUCYL THIAZOLIDINE FUMARATE; PEPTIDASE; QUIESCENT CELL PROLINE DIPEPTIDASE; UNCLASSIFIED DRUG;

ALOPECIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG CLASSIFICATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MALE; MORTALITY; MOUSE; MULTIPLE ORGAN FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; RAT; RETICULOCYTE; SPLENOMEGALY; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TOXICITY TESTING;

ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; DIPEPTIDASES; DIPEPTIDYL PEPTIDASES; DOGS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; ISOLEUCINE; ISOMERISM; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEASE INHIBITORS; RATS; RECOMBINANT PROTEINS; THIAZOLES;

EID: 25844459084     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.10.2988     Document Type: Article

References (30)

1. Deacon CF, Ahrén B, Holst J: Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 13:1091-1102, 2004
2. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084, 2004
3. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880, 2004
4. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Nat Acad Sci 97:6874-6879, 2000
5. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zycband E, Moller DE, Thornberry NA, Zhang BB: Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Nat Acad Sci 100:6825-6830, 2003
6. Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929-2940, 2003
7. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
8. Kieffer TJ, McIntosh CHS, Pederson TA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrin 136:3585-3596, 1995
9. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
10. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331, 1999
11. Šedo A, Malík R: Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta 1550:107-116, 2001
12. Underwood R, Chiravuri H, Lee H, Schmitz R, Kabcenell AK, Yardley K, Huber BT: Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem 274:34053-34058, 1999
13. Abbott CA, Yu CM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD: Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 267:6140-650, 2000
14. Ajami K, Abbott CA, McCaughan W, Gorrell MD: Dipeptidyl peptidase 9 has two forms, abroad tissue distribution, cytoplasmic localization, and DPIV-like peptidase activity. Bichemica et Biophysica Acta 1679:18-28, 2004
15. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ: Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274:36505-36512, 1999
16. Duke-Cohan JS, Gu J, McLaughlin DF, Xu Y, Freeman GJ, Schlossman SF: Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions. Proc Nat Acad Sci 95:11336-11341, 1998
17. Blanco J, Jacotot E, Callebaut C, Krust B, Hovanessian AG: Dipeptidyl-peptidase IV-β: further characterization and comparison to dipeptidyl-peptidase IV activity of CD26. Eur J Biochem 256:369-378, 1998
18. Chen W-T, Kelly T, Ghersi G: DPPIV, seprase, and related serine peptidases in multiple cellular functions. Curr Topics Develop Biol 54:207-232, 2003
19. De Meester I, Korom S, Van Damme J, Scharpe S: CD26, let it cut or cut it down. Immunology Today 20:367-375, 1999
20. Reinhold D, Kahne T, Steinbrecher A, Wrenger S, Neubert K, Ansorge S, Brocke S: The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Biol Chem 383:1133-1138, 2002
21. Beconi MG, Mao A, Liu DQ, Kochansky C, Pereira T, Raab C, Pearson P, Lee Chiu SH: Metabolism and pharmcokinetics of a dipeptidyl peptidase IV inhibitor in rats, dogs, and monkeys with selective carbamoyl glucurpnidation of the primary amine in dogs. Drug Metab Dispos 31:1269-1277, 2003
22. Weber AE: Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 47:4135-4141, 2004
23. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA: Long-term treatment with dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell responsiveness in VDF (fa/fa) Zucker rat. Diabetes 51:943-950, 2002
24. Pauly RP, Demuth HU, Rosche R, Schmidt J, White HA, McIntosh CHS, Pederson RA: Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance (Abstract). Regul Pept 64:148, 1996
25. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth H-U: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidine. Diabetes 47:1253-1258, 1998
26. Pospisilik JA, Stafford SG, Demuth H-U, McIntosh CHS, Pederson RA: Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat. Diabetes 51:2677-2683, 2002
27. Jiaang W, Chen Y, Hsu T, Wu S, Chien C, Chang C, Chang S, Lee S, Chen X: Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Letters 15:687-691, 2005
28. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Sinha Roy R, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE: (2R)4-Oxo4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151, 2005
29. Edmondson SD, Mastracchio A, Beconi M, Colwell LF, Habulihaz B, He H, Kumar S, Leiting B, Lyons KA, Mao A, Marsilio F, Patel RA, Wu JK, Zhu L, Thornberry NA, Weber AE, Parmee ER: Potent and selective proline derived dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 14:5151-5155, 2004
30. Parker JC, Hulin B, Vanvolkenburg MA, Lopaze MG, Sagawa K, Ogorman MT, Gerdin K, Andrews KM, Brees DJ, Reagan WJ: A novel fluorinated cyclic amide inhibitor of dipeptidyl peptidase IV improves glucose tolerance in murine models of diabetes mellitus (Abstract). Diabetes 52 (Suppl. 1) (16-late-breaking abstract), 2003